Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 112Lung Neoplasms 83Lymphoma 76Head and Neck Neoplasms 76Glioblastoma 75Squamous Cell Carcinoma of Head and Neck 71Breast Neoplasms 71Rectal Neoplasms 66Esophageal Neoplasms 63Prostatic Neoplasms 59Leukemia 57Central Nervous System Neoplasms 54Pancreatic Neoplasms 51Precursor Cell Lymphoblastic Leukemia-Lymphoma 47Lymphoma, Non-Hodgkin 43Lymphoma, Large B-Cell, Diffuse 43Hodgkin Disease 42Lymphoma, Follicular 41Brain Neoplasms 40Leukemia, Lymphocytic, Chronic, B-Cell 39Esophageal Squamous Cell Carcinoma 39Colorectal Neoplasms 38Burkitt Lymphoma 37Gliosarcoma 36Lymphoma, Large-Cell, Immunoblastic 33Uterine Cervical Neoplasms 31Neoplasms 31Adenocarcinoma Of Esophagus 31Lymphoma, Mantle-Cell 30Lymphoma, B-Cell, Marginal Zone 29

Interventions

Leucovorin 2Fluorouracil 2Cetuximab 2Bevacizumab 2spartalizumab 1sintilimab 1Radiotherapy 1Radiation Dose Hypofractionation 1Oxaliplatin 1Irinotecan 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Locally Recurrent Rectal Cancer × Radiotherapy × Clear all
NCT07183865 2025-09-19

Hypofractionated Radiotherapy Combined With NALIRIF, PD-1 Antibody in Locally Recurrent Rectal Cancer(NOVELTY-R)

Fudan University

Phase 2 Recruiting
44 enrolled
Gastrointestinal

Locally Recurrent Rectal Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡